Supplementary Table 2 from Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT–Controlled Prospective Study in 64 Patients

Mayerhoefer, Marius E.; Karanikas, Georgios; Kletter, Kurt; Prosch, Helmut; Kiesewetter, Barbara; Skrabs, Cathrin; Porpaczy, Edit; Weber, Michael; Knogler, Thomas; Sillaber, Christian; Jaeger, Ulrich; Simonitsch-Klupp, Ingrid; Ubl, Philipp; Müllauer, Leonhard; Dolak, Werner; Lukas, Julius; Raderer, Markus

doi:10.1158/1078-0432.22459235.v1

- No file added yet -

Supplementary Table 2 from Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT–Controlled Prospective Study in 64 Patients

journal contribution

posted on 2023-03-31, 18:49 authored by Marius E. Mayerhoefer, Georgios Karanikas, Kurt Kletter, Helmut Prosch, Barbara Kiesewetter, Cathrin Skrabs, Edit Porpaczy, Michael Weber, Thomas Knogler, Christian Sillaber, Ulrich Jaeger, Ingrid Simonitsch-Klupp, Philipp Ubl, Leonhard Müllauer, Werner Dolak, Julius Lukas, Markus Raderer

Supplementary Table 2. True positive (TP), false negative (FN), false positive (FP), and true negative (TN) regions for DWI-MRI at follow-up, relative to 18F-FDG-PET/CT

History

ARTICLE ABSTRACT

Purpose: To determine the value of diffusion-weighted MRI (DWI-MRI) for treatment response assessment in 2-[18F]fluoro-2-deoxy-D-glucose (FDG)–avid lymphoma.Experimental Design: Patients with FDG-avid Hodgkin (HL) or non-Hodgkin lymphoma (NHL) at pretherapeutic 18F-FDG-PET/CT, who had also undergone pretherapeutic whole-body DWI-MRI, were included in this prospective study. Depending on the histologic lymphoma subtype, patients received different systemic treatment regimens, and follow-up DWI-MRI and 18F-FDG-PET/CT were performed at one or more time points, depending on the clinical course. For each follow-up DWI-MRI, region-based rates of agreement, and rates of agreement in terms of treatment response (complete remission, partial remission, stable disease, or progressive disease), relative to the corresponding 18F-FDG-PET/CT, were calculated.Results: Sixty-four patients were included: 10 with HL, 22 with aggressive NHL, and 32 with indolent NHL. The overall region-based agreement of DWI-MRI with 18F-FDG-PET/CT was 99.4%. For the 51 interim examinations (performed after 1–3 therapy cycles), region-based agreement of DWI-MRI with 18F-FDG-PET/CT was 99.2%, and for the 48 end-of-treatment examinations, agreement was 99.8%. No significant differences, in terms of region-based agreement between DWI-MRI and 18F-FDG-PET/CT, were observed between the three lymphoma groups (HL, aggressive NHL, indolent NHL; P = 0.25), or between interim and end-of-treatment examinations (P = 0.21). With regard to treatment response assessment, DWI-MRI agreed with 18F-FDG-PET/CT in 99 of 102 follow-up examinations (97.1%), with a κ value of 0.94 (P < 0.0001).Conclusions: In patients with FDG-avid lymphoma, DWI-MRI may be a feasible alternative to 18F-FDG-PET/CT for follow-up and treatment response assessment. Clin Cancer Res; 21(11); 2506–13. ©2015 AACR.